Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31772118.
- Also identified by DOI 10.1158/1078-0432.CCR-19-3645.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metformin is an affordable and well-tolerated drug used in type 2 diabetes. Potential anticancer effects of metformin in gynecologic malignancies include inhibition of the PI3K-mTOR pathway, hormone receptor regulation, and reduction of fibrosis and inflammation. Multiple studies are currently assessing its role in cancer prevention and as a treatment enhancer.<i>See related articles by Soliman et al., p. 581, and McCloskey et al., p. 632</i>.
Medical subject headings
- Diabetes Mellitus, Type 2
- Genital Neoplasms, Female
- Metformin